31 January 2022>: Meta-Analysis
Utility of Pretreatment Blood Platelet-To-Lymphocyte Ratio in Prediction of Clinical Outcomes and Chemosensitivity in Patients with Advanced Gastric Cancer: A Meta-Analysis
Xiulan Peng 1AE* , Wei Zeng 2BF* , Bing Tang 3CF* , Anbing He 1B , Min Zhang 1B , Renfeng Luo 4AB*DOI: 10.12659/MSM.933449
Med Sci Monit 2022; 28:e933449
Table 2 Subgroup analyses of pooled HRs and 95% CIs for OS based on different factors.
Subgroup analysis | No. of studies | No. of patients | Effects model | HR (95% CI) | P value | Heterogeneity | |
---|---|---|---|---|---|---|---|
I2 (%) | p value | ||||||
OS | |||||||
NOS score | |||||||
>7 | 9 | 2190 | Random | 1.36 (1.08–1.72) | 0.010 | 70.8 | 0.001 |
≤7 | 7 | 963 | Fixed | 1.46 (1.29–1.65) | 16.1 | 0.303 | |
Sample size | |||||||
≥168 | 8 | 2453 | Fixed | 1.53 (1.37–1.70) | 15.5 | 0.308 | |
8 | 700 | Random | 1.37 (1.05–1.80) | 0.020 | 64.1 | 0.007 | |
Treatment | |||||||
Chemotherapy | 10 | 2090 | Random | 1.34 (1.11–1.62) | 0.002 | 63.7 | 0.003 |
Mixed | 6 | 1063 | Fixed | 1.62 (1.39–1.89) | 0.0 | 0.646 | |
Cut-off value | |||||||
≥161 | 9 | 1836 | Fixed | 1.37 (1.22–1.53) | 37.3 | 0.120 | |
7 | 1317 | Random | 1.41 (1.11–1.80) | 0.005 | 68.6 | 0.004 | |
Cut-off method | |||||||
ROC curve | 8 | 1687 | Fixed | 1.48 (1.29–1.71) | 41.7 | 0.100 | |
Median | 4 | 787 | Random | 1.22 (0.88–1.70) | 0.238 | 78.0 | 0.003 |
NA | 3 | 375 | Fixed | 1.62 (1.34–1.95) | 0.0 | 0.774 | |
X-title | 1 | 304 | – | 1.59 (1.02–2.48) | 0.041 | – | – |
Ethnicity | |||||||
Caucasian | 3 | 369 | Random | 1.30 (0.71–2.39) | 0.394 | 87.8 | |
Asian | 13 | 2784 | Fixed | 1.43 (1.30–1.58) | 25.1 | 0.190 | |
Total | 16 | 3153 | Random | 1.43 (1.25–1.64) | 54.1 | 0.005 | |
CI – confidence interval; HR – hazard ratio; OS – overall survival; DFS – disease-free survival; ROC – receiver operating characteristics curve; PLR – platelet to lymphocyte ratio (I >50% or |